Daiichi commits up to $650M to Charleston Labs for nausea drugs

Daiichi Sankyo Co. Ltd. is investing up to $650 million in a Charleston Laboratories Inc. subsidiary to back development and U.S. commercialization of its hydrocodone combination drug portfolio, including CL-108, a late-stage therapy providing the pain relief of hydrocodone without the common nausea and vomiting associated with the widely prescribed opioid.